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Abstract We have recently identified the fifth member of the
membrane-type matrix metalloproteinase subfamily, MT5-
MMP/MMP24, which is expressed in a brain specific manner
(Duanqing Pei (1999) J. Biol. Chem. 274, 8925^8932). To
further characterize its enzymic properties, an expression
construct was engineered to produce MT5-MMP as a soluble
and active form by truncating its transmembrane domain. Stable
expression cell lines were subsequently established from MDCK
cells transfected with this construct. Unfortunately, purification
of MT5-MMP from the culture media in large quantity proves to
be difficult initially due to its rapid turnover via a mechanism
which can be inhibited by a broad spectrum metalloproteinase
inhibitor, BB94. Thus, BB94 was included in the cell culture
medium and throughout the purification process except the final
step of chromatography to protect MT5-MMP from destruction.
Purified to homogeneity and free of the synthetic inhibitor, MT5-
MMP can activate progelatinase A efficiently in a TIMP2
sensitive fashion. A preliminary screen for its potential substrates
among extracellular matrix components identified the proteogly-
cans as the preferred substrates for MT5-MMP. Furthermore, it
is determined that the stability of purified MT5-MMP is
temperature dependent with rapid destruction at 37‡C, but being
relatively stable at temperatures 4‡C or lower. These observa-
tions establish MT5-MMP as a proteoglycanase with a short
half-life at body temperature, which may be critical for tightly
controlled turnover of ECM components such as those in the
brain.
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1. Introduction
The extracellular matrix (ECM) undergoes extensive remod-
eling under both physiological as well as pathological condi-
tions [1^3]. Among the proteinases discovered so far, members
of the matrix metalloproteinase (MMP) family have been
singled out as the main mediators of ECM destruction by
virtue of their abilities to degrade all ECM components under
physiological conditions [2,3]. Indeed, the expression of one or
multiple MMPs has been documented extensively in tissues or
organ sites under active ECM remodeling [2,4,5]. However,
the relative contribution of individual MMPs toward tissue
destruction remains poorly de¢ned.
Among MMPs discovered so far, two main categories can
be recognized based on their cellular localizations: soluble vs.
membrane-bound. The soluble MMPs are divided into the
collagenases (MMP1, MMP8 and MMP13). gelatinases
(MMP2 and MMP9), stromelysins (MMP3, MMP12) and
those yet to be classi¢ed such as MMP7, MMP11, MMP18/
19, etc. [5,6]. The membrane-bound subfamily currently has
¢ve members: MT1, 2, 3, 4, and 5-MMPs with a characteristic
transmembrane segment at their C-termini [7^11]. Although
localized di¡erently, these two classes of MMPs are expected
to cooperate in ECM degradations. In fact, a well-de¢ned
property of the MT-MMPs is their ability to interact with
and activate the proforms of MMP2 and MMP13, thus form-
ing a proteolytic complex on cell surface [7,8,11^13]. With the
expansion of the MT-MMP subfamily, it becomes apparent
that they play a far greater role in ECM remodeling events
than zymogen activation. For example, MT1, 2, 3-MMPs
have been demonstrated to have powerful intrinsic activities
toward ECM components such as ¢bronectin, laminin, type I
and III collagens, nidogen, tenascin, aggrecan and perlecan,
thus, demonstrating a degree of versatility for these important
enzymes under many physiological as well as pathological
states [14^19]. Thus, there have been intense interests in the
characterization of these membrane-bound MMPs as central
regulators of ECM degradation [20,21].
MT5-MMP, the latest addition to this subfamily with a
serial designation as MMP24, is a brain speci¢c MT-MMP
capable of activating progelatinase A [11]. It is signi¢cant that
brain is the main adult organ expressing high level of MT5-
MMP message RNA because other MT-MMPs have much
broader tissue distributions [7^11]. Furthermore, MT5-MMP
exhibits an unusual tendency to be shed from cell surface [11].
Despite these interesting properties, the role of MT5-MMP in
tissue remodeling events remains unde¢ned. To begin to
understand its enzymic potentials, we report here the expres-
sion, puri¢cation and characterization of MT5-MMP active
enzyme. With a short half-life as an active proteinase, MT5-
MMP appears to be an e⁄cient proteinase against proteogly-
can components of the extracellular matrix.
2. Materials and methods
2.1. Cell lines and reagents
MDCK cells were obtained and maintained as described previously
[11]. General chemical reagents were from Fisher Scienti¢c (Pitts-
burgh, PA, USA). Reagents for DNA restriction and modi¢cation
were from Promega (Madison, WI, USA). Tissue culture media and
reagents were from Gibco-BRL (Rockville, MD, USA). Oligonucleo-
tide primers were made by the University of Minnesota microchemical
core facility. ECM components were purchased from Collaborative
Research (Boston, MA, USA). FLAG peptides, anti-FLAG M2 anti-
body and M2 a⁄nity agarose gel were purchased from Sigma (St.
Louis, MO, USA). Rabbit polyclonal anti-MT5-MMP antisera were
prepared as described previously [22].
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2.2. Construction of expression vectors and generation of stable cell
lines
The expression vector for full-length MT5-MMP as well as its sta-
ble transfectant MT591 have been described [11]. The sequence encod-
ing MT5-MMP1ÿ570 was isolated by high-¢delity PCR with the pfu
polymerase employing two primers: T3 primer (on the pBluescript
vector) and the 3P MT5-MMP speci¢c primer GTC ACT TGT
CAT CGA CGT CCT TGT AGT CGT TCA CAG AGC CTG
GCA C. The fragment was subsequently cloned into pCR3.1uni ex-
pression vector and characterized as described previously [11]. Since
the 3P end primer also contains the FLAG sequence, the resulting
protein is tagged with the FLAG epitope to facilitate detection and
puri¢cation. The resulting expression vector was transfected into
MDCK cells and stable clones were established by neomycin selection
as described [23]. One of the clones, MT5v44, was selected for further
studies based on a relatively high level of expression for MT5-
MMP1ÿ570.
2.3. Puri¢cation and characterization of MT5-MMP products
MT5v44 cells were grown to con£uence and washed with phos-
phate-bu¡ered saline three times before fresh medium was added.
Due to stability concerns, we have puri¢ed MT5-MMP with or with-
out BB94 (5 WM). For puri¢cation without BB94, all steps from con-
ditioned medium collection to a⁄nity chromatography were carried
out free of this inhibitor. For the ones with BB94, it was included
throughout the puri¢cation procedure except the ¢nal immuno-a⁄nity
step to protect MT5-MMP from auto-degradation. Brie£y, the con-
ditioned medium was ¢rst cleared of debris by centrifugation at 20 000
rpm, loaded onto a Q-sepharose column (2U20 cm) and eluted with a
gradient of 0.15 to 1 M NaCl as described [14]. Positive fractions were
identi¢ed by Western blotting, pooled together and then stored at
380‡C. The ¢nal puri¢cation step was accomplished with an immu-
no-a⁄nity column made of anti-FLAG M2 monoclonal antibody
(Sigma, St. Louis, MO, USA). The Q-sepharose fractions were loaded
onto a pre-washed M2 column twice to maximize the binding. Un-
bound materials as well as residual BB94 were removed by extensive
washing with Tris-bu¡ered saline (TBS, 150 mM NaCl, 50 mM Tris-
HCl, 5 mM CaCl2, 0.1% Brij35). The bound materials were eluted
with two column equivalents of FLAG peptides in TBS. The puri¢ed
materials were analyzed by SDS-PAGE, Western blotting and zymo-
graphy, as described [14].
Substrate degradation experiments were carried out essentially as
described [14]. Brie£y, ECM substrates (2^5 Wg) were incubated with
various amounts of puri¢ed MT5-MMP (10^160 ng) in the activity
bu¡er (150 mM NaCl, 50 mM Tris-HCl, 5 mM CaCl2, 1 mM ZnCl2,
0.1% Brij 35) at 37‡C for 2 to 24 h. Degradation of native type I
collagen was carried out in the presence of 100 mM arginine at 25‡C
with the same activity bu¡er as above. The reaction mixtures were
analyzed by SDS-PAGE and visualized by Coomassie staining as
described [14].
The stability of MT5-MMP is determined by incubating the same
amount of puri¢ed MT5-MMP at 4‡C, 20‡C and 37‡C in the activity
bu¡er or the same bu¡er without Brij35 for 0 min, 30 min, 1 h, 3 h
and 24 h. At each time point, reactions were stopped with SDS-PAGE
sample bu¡er before being stored at 380‡C. The reaction mixtures
were analyzed by Western blotting using anti-MT5-MMP antisera
[11].
3. Results
3.1. Expression of MT5-MMP as a soluble and active enzyme
As reported previously, MT5-MMP was identi¢ed as a
membrane-anchored proteinase and soluble ones shed from
cell surface [11]. To further characterize the enzymic proper-
ties of MT5-MMP, an expression vector was engineered to
express a fully secretory form of MT5-MMP by deleting the
transmembrane domain, i.e. the full-length ecto-enzyme (Fig.
1A). A FLAG tag was fused at the C-terminus to facilitate
detection and puri¢cation as described previously (Fig. 1A,
[23]). Based on previous experience with MT1-MMP, the
ecto-enzyme should be synthesized as a proenzyme and proc-
essed in the trans-Golgi network into active species prior to
secretion by furin or related proprotein convertases recogniz-
ing the RXKR motif sandwiched between its pro- and cata-
lytic domains [14]. Indeed, transient transfection of the vector
carrying MT5-MMP1ÿ570 into COS cells yielded MT5-MMP
as a secreted form (data not shown). Stable cell lines were
subsequently established to express MT5-MMP1ÿ570 in
MDCK cells as described [23]. One of them, MT5v44, was
chosen for further characterization for its relatively high yield
of the secreted MT5-MMP proteinases. To compare between
secretion of the ecto-enzyme and shedding of the full-length
molecule, serum-free conditioned media were collected in the
absence or presence of BB94 (50 WM) from MT5v44 cells as
well as MT591, a cell line expressing the full-length construct,
and subsequently analyzed by zymography and Western blot-
ting. As reported previously, MT591 sheds into the condi-
tioned medium a predominantly 28 kDa gelatinolytic species
which is reduced in the presence of BB94 with concomitant
increase of higher molecular weight forms (Fig. 1B, lanes 3 vs.
4, [11]). As expected, MT5v44 cells secrete a combination of
gelatinolytic species ranging from 28 to 58 kDa (Fig. 1B, lanes
5 and 6). Curiously, a 28 kDa species, apparently identical to
the one shed from MT591, is also present in conditioned
medium from MT5v44 cells (Fig. 1B, lower arrowhead). In
addition, a major species around 58 kDa and minor ones at
40 and 49 kDa were also detected from MT5v44 cells (Fig.
1B, lanes 5 and 6, upper arrowhead and short/long arrows).
The multiple banding pattern on zymography suggests that
the 58 kDa active MT5-MMP species may autocatalytically
process itself into smaller species (Fig. 1B, lane 5). To test this
possibility, BB94, a synthetic MMP inhibitor, was added to
the culture medium to prevent the autocatalytic processing.
As shown in Fig. 1B, BB94 in general inhibited the levels of
the smaller molecular weight forms of MT5-MMP and pro-
tected the larger species (lanes 4 and 6). In fact, the 58 kDa
species was stabilized enough for further puri¢cation. For
reason unclear, BB94 also altered the apparent migration
rate of progelatinase B in all three cell lines analyzed (Fig.
1B). To con¢rm the identity of putative MT5-MMP gelatino-
lytic activity identi¢ed on zymography, BB94-containing con-
ditioned media from control, MT591 and MT5v44 cells were
analyzed by Western blotting using MT5-MMP antisera. As
shown in the right panel of Fig. 1B, a major 58 kDa species,
as well as minor smaller species were identi¢ed only in the
MT5v44 cells, not in the control or MT591 cells (lane 9),
consistent with the zymography data described above.
3.2. Puri¢cation of MT5-MMP protein products
Based on data from Fig. 1, it is apparent that MT5-MMP
undergoes extensive processing after secretion into the condi-
tioned medium, and consequently, fails to accumulate signi¢-
cantly as a full-length ecto-enzyme in the culture medium
without supplementing BB94. Thus, BB94 becomes a critical
supplement in the puri¢cation procedure to prevent the frag-
mentation of the full-length MT5-MMP ecto-enzyme similar
to that described for the puri¢cation of stromelysin-3 [22]. As
described in Section 2, conditioned media were collected from
MT5v44 cells without or with BB94 (5 WM) and subjected to
chromatography, ¢rst on a Q-sepharose column, then, an
anti-FLAG M2 immuno-a⁄nity column. At the ¢nal elution
step during a⁄nity chromatography, the columns were
washed extensively with at least 15U of the column volume,
and the bound materials were eluted competitively with
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FLAG peptide at 2:1 molar ratio (peptide:antibody). For the
puri¢cation of MT5-MMP in the presence of BB94, the ¢nal
wash step was carried out without the inhibitor to remove the
residual inhibitor from the bound materials. To evaluate the
puri¢cation procedures, the starting medium, £ow-through
and eluted materials were analyzed by SDS-PAGE followed
by Coomassie staining (Fig. 2, lanes 2^4 and 8^10). The eluted
products were further analyzed by immunoblotting with both
anti-MT5 and anti-FLAG antibody, or zymography (Fig. 2,
lanes 5^7 and 11^13). As shown in Fig. 2, the ¢nal puri¢ed
products (lanes 4 and 10) are signi¢cantly di¡erent between
procedures with or without BB94. In the absence of BB94,
MT5-MMP was puri¢ed as a mixture of fragments ranging
from 45^58 kDa, whereas only the 58 kDa species was ob-
tained in its presence with a signi¢cantly higher yield (lanes 4
vs. 10 of Fig. 2). Since the proteins were puri¢ed with the anti-
FLAG M2 a⁄nity column, all eluted products should contain
an intact FLAG epitope at the C-termini. Thus, only the
largest species at 58 kDa represents the full-length ecto-en-
zyme whereas the smaller species have N-terminal truncation
in the catalytic domain. Indeed, all eluted proteins visualized
by SDS-PAGE/Coomassie staining were also detected by anti-
FLAG antibody, suggesting the presence of the FLAG epi-
tope (Fig. 2, lanes 5 and 11). On the other hand, the 28 kDa
gelatinolytic species present in the conditioned medium of
MT5v44 cells were not recovered during this puri¢cation pro-
cedure due to their lack of intact C-termini to which the
FLAG tag was linked, thus, failed to bind to the M2 a⁄nity
column. Nevertheless, all puri¢ed products appear to be MT5-
MMP derived protein products since they can all be detected
by anti-MT5-MMP antisera (lanes 6 and 12).
Smaller fragments of MT5-MMP are only present in the
eluted products puri¢ed without BB94, but absent from those
puri¢ed in the presence of BB94 (Fig. 2, lanes 6 and 12). Since
these smaller fragments were also reactive to M2 antibody,
they are truncated at the N-termini, i.e. the catalytic domain,
potentially rendering the remaining molecule inactive (Fig. 2,
lanes 5 and 11). Indeed, when the puri¢ed products were
analyzed by zymography, only the full-length ecto-enzyme
exhibited gelatinolytic activity, suggesting that the smaller
fragments were indeed truncated in the catalytic domain of
MT5-MMP (Fig. 2, lanes 7 and 13). Thus, the synthetic in-
hibitor, BB94, is critical in the puri¢cation of full-length MT5-
MMP ecto-enzyme, providing at least ¢ve fold more full-
length ecto-MT5-MMP enzyme.
3.3. Enzymic function of MT5-MMP
Based on zymography, it is clear that MT5-MMP degrades
gelatin e⁄ciently (Fig. 1B). To begin to analyze the enzymic
properties of MT5-MMP, we examined its activity against
gelatin in a dose dependent manner. Signi¢cant degradation
of gelatin was observed with as little as 20 ng of enzyme in a
2 h incubation period (Fig. 3A, lane 3). All gelatin substrates
were completely destroyed by 160 ng of enzyme under iden-
tical conditions (Fig. 3A, lane 6). At the mean time, known
MMP inhibitors such as EDTA, BB94 and TIMP2 completely
blocked the activity of MT5-MMP (Fig. 3A, lanes 7^9). It is
interesting that the inhibitors blocked not only substrate deg-
Fig. 1. Expression of mouse MT5-MMP as a soluble, processed ecto-enzyme in mammalian cells. A: Domain structures of wild-type (upper),
ecto- (middle) and fully processed ecto- (lower) MT5-MMPs are presented schematically (see Section 2). The ecto-portion of MT5-MMP
(MT5-MMP1ÿ570) is tagged with a FLAG epitope for detection and puri¢cation. Pro: prodomain; S: stem; T: transmembrane; C: cytosolic
tail ; F: FLAG. B: Stable expression of MT5-MMP as a soluble enzyme. MDCK cells were transfected stably with control (lanes 1, 2 and 7),
full-length (lanes 3, 4 and 8) and ecto- (lanes 5, 6 and 9) MT5-MMP expression constructs, to generate the corresponding cell lines: control,
MT591 and MT5v44 as described in Section 2. Con£uent cultures were washed three times in PBS and allowed to be conditioned under se-
rum-free condition in the absence (lanes 1, 3 and 5) or presence (lanes 2, 4, 6^9) of BB94 (50 WM) for 48 h. The harvested supernatants were
analyzed by zymography (lanes 1^6) or Western blotting (lanes 7^9) as described [11]. CK: control, Gel B: gelatinase B; MT5: MT5-MMP.
FEBS 22966 26-11-99
X. Wang et al./FEBS Letters 462 (1999) 261^266 263
radation, but also the fragmentation of enzyme itself (Fig. 3A,
lanes 6 vs. 7^9).
To con¢rm that the puri¢ed enzyme has similar properties
as the native enzyme, we tested its ability to activate gelatinase
A, the putative physiological substrate for the MT5-MMP. As
shown in Fig. 3B, MT5-MMP activated progelatinase A to
completion (lane 2), in a manner sensitive to MMP inhibitor
BB94 as expected (Fig. 3B, lane 3).
3.4. Substrate pro¢le of MT5-MMP
To further analyze the proteolytic properties of MT5-
MMP, the puri¢ed enzyme was incubated with various extra-
cellular matrix components including ¢bronectin, laminin,
chondroitin sulfate proteoglycans, type I collagen and derma-
tan sulfate proteoglycans as described previously [14]. The
resulting reaction mixtures were analyzed as described in Sec-
tion 2 to monitor any potential degradation. As shown in Fig.
4, the proteoglycans were degraded completely by MT5-MMP
(lanes 12 and 18) in a BB94 sensitive fashion (lanes 13 and
19). In addition, MT5-MMP degraded ¢bronectin partially
under similar conditions (Fig. 4, lane 6). Type I collagen
and laminin are apparently resistant to MT5-MMP (lanes 6
and 9).
3.5. Stability of MT5-MMP
While characterizing the enzymic properties of the puri¢ed
MT5-MMP products, we noticed a steady decrease in the
amount of enzyme in the reaction mixtures without MMP
inhibitors (Fig. 3A). Since no other proteolytic enzymes are
present in the reaction bu¡er, it is highly likely that the decay
is autocatalytic, consistent with a similar observation made
Fig. 2. Puri¢cation and analysis of MT5-MMP ecto-enzyme. Serum-
free media conditioned from the stable cell line MT5v44 in the ab-
sence (A) or presence (B) of MMP inhibitor BB94 (5 WM) were
fractionated on Q-sepharose ion exchange columns with or without
BB94 (5 WM) as indicated. MT5-MMP positive fractions were
pooled (lanes 2 and 8) and loaded onto M2-agarose column twice.
Most of the proteins £ow through without binding to the column
(lanes 3 and 9). After washing to remove unbound materials and
BB94, the columns were eluted with 2 column equivalents of FLAG
peptide to give rise to puri¢ed MT5-MMP materials (lanes 4^7, 10^
13). Materials from each step (20 Wl per lane) were analyzed by
SDS-PAGE stained with Coomassie (lanes 1^4, 8^10). The puri¢ed
materials (50 ng each) were analyzed by Western blotting using
anti-FLAG monoclonal antibody (lanes 5 and 11) or rabbit polyclo-
nal antisera raised against human GST-MT5-MMP fusion protein
(lanes 6 and 12), or gelatin zymography (lanes 7 and 13) as de-
scribed [11]. The arrowheads indicate MT5-MMP ecto-enzymes. The
bracket marks MT5-MMP fragments generated in the absence of
BB94.
Fig. 3. Proteolytic activity of MT5-MMP ecto-enzyme. A: Degrada-
tion of gelatin by MT5-MMP and inhibition by EDTA, BB94 and
TIMP2. Gelatin (5 Wg) was incubated either alone (lane 2), or puri-
¢ed MT5-MMP at a dose of 20 ng (lane 3), 40 ng (lane 4), 80 ng
(lane 5) and 160 ng (lanes 6^9) for 2 h at 37‡C. Metalloproteinase
inhibitors, EDTA (10 mM, lane 7), BB94 (2.5 WM, lane 8) or TIMP
2 (300 ng lane 9), were added individually into the selected reactions
as indicated. At the end of the experiment, portions of each reaction
(V1.5 Wg of gelatin) were analyzed by SDS-PAGE which was
stained with Coomassie blue. B: Activation of progelatinase A by
puri¢ed MT5-MMP. Progelatinase A from COS conditioned media
(20 ml unconcentrated) were either incubated alone (lane 1) or with
puri¢ed MT5-MMP (40 ng) without (lane 2) or with (lane 3) 2.5
mM of BB94 for 24 h at 37‡C. The reaction mixtures were analyzed
by gelatin zymography.
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during the puri¢cation procedure (Fig. 2A). Since the stability
of an enzyme a¡ects the kinetics of its substrate degradation,
it becomes critical to determine the rate by which MT5-MMP
decays autocatalytically. To this end, the puri¢ed MT5-MMP
was incubated at various temperatures under the identical
bu¡er system used for substrate characterization. As shown
in Fig. 5, MT5-MMP fragments itself rapidly at 37‡C. More
than 50% of the enzyme is converted into smaller fragments
within 30 min of incubation (Fig. 5, lane 7). The enzyme is
even less stable in the absence of Brij 35 (Fig. 5, lane 8).
Within 24 h, MT5-MMP lost all its activity at 37‡C, and
almost 95% at 20‡C (Fig. 5, lanes 18^20). At lower temper-
ature, however, MT5-MMP was relatively stable, able to
maintain almost 45% of the enzyme in its original form after
24 h (Fig. 5, lane 17). Based on these observations, it is con-
cluded that MT5-MMP has a relatively short half-life.
4. Discussion
Currently, ¢ve distinct members of the MT-MMP subfam-
ily have been identi¢ed and characterized [7^11]. One of the
hallmark functions for MT-MMPs is their ability to activate
progelatinase A on cell surface [7,13]. The exception is per-
haps MT4-MMP whose ability to activate progelatinase A has
yet to be demonstrated. Based on sequence similarity analysis,
MT4-MMP appears to be quiet distant from the rest of the
MT-MMP members [6,11], thus, may have di¡erent enzymic
properties. In addition to progelatinase A, MT1-MMP has
been shown to be able to activate procollagenase 3 [12].
Thus, it appears that the primary function for MT-MMPs is
to activate a selective group of proMMPs. However, with the
expansion of the MT-MMP subfamily, it is unlikely that these
¢ve membrane-bound MMPs have been evolved solely to
serve as activators for progelatinase A or procollagenase 3.
In this report, we demonstrated that MT5-MMP degrades
ECM components directly against at least two proteoglycans-
dermatan sulfate proteoglycans and chondroitin sulfate pro-
teoglycans (Fig. 4). By expressing MT5-MMP as a truncated
form lacking its transmembrane domain, we were able to pu-
rify the ecto-enzyme of MT5-MMP into homogeneity. The
availability of this enzyme preparation made it possible to
characterize the properties of MT5-MMP in further details.
First of all, puri¢ed MT5-MMP activates progelatinase A as
predicted from previous co-transfection experiments [11].
More signi¢cantly, we also demonstrated that MT5-MMP
has intrinsic matrix degrading activity. This is in general
agreement with the view that MT-MMPs are powerful matrix
degrading enzymes themselves, a notion ¢rst demonstrated for
MT1-MMP by engineering and purifying its ecto-enzyme [14].
It was subsequently con¢rmed, expanded and extended to
MT2, 3-MMPs [15,16,18,24,25]. As a group, MT-MMPs
have been shown to be able to degrade ¢bronectin, laminin,
type I, II and III collagen, nidogen, tenascin, aggrecan and
perlecan [15,16,18,24,25]. With the availability of puri¢ed en-
zymes, it will be interesting to compare and contrast directly
their activities towards not only the traditional substrates such
Fig. 4. ECM degradation by MT5-MMP. ECM components (2 Wg each) including gelatin (GN, lanes 2^4), ¢bronectin (FN, lanes 5^7), laminin
(LN, lanes 8^10), chondroitin sulfate proteoglycan (CSPG, lanes 11^13), native type I collagen (type I, lanes 14^16) and dematin sulfate proteo-
glycan (DSPG, lanes 17^19) were either incubated alone (lanes 2, 5, 8, 11, 14 and 17) or with puri¢ed MT5-MMP (50 ng, lanes 3, 4, 6, 7, 9,
10, 12, 13, 15, 16, 18 and 19) in absence (lanes 3, 6, 9, 12, 15 and 18) or presence (lanes 4, 7, 10, 13, 16 and 19) of BB94 (5 WM) for 24 h at
37‡C (lanes 2^13, 17^19) or 25‡C (lanes 14^16). The reaction mixtures were then analyzed by SDS-PAGE and stained as described [14].
Fig. 5. Stability of MT5-MMP. Puri¢ed MT5-MMP (40 ng per reaction) was incubated at 4‡C, 20‡C, or 37‡C for 0 min, 30 min, 1 h, 3 h, and
24 h as indicated. Reactions were terminated by boiling in SDS-PAGE sample bu¡er and analyzed by Western blotting using rabbit polyclonal
anti-MT5-MMP antisera as described previously [11]. * indicates the incubation bu¡er without 0.1% Brij.
FEBS 22966 26-11-99
X. Wang et al./FEBS Letters 462 (1999) 261^266 265
as progelatinase A or procollagenase 3, but also many ECM
components.
By design, this study focused on the full-length ecto-enzyme
of MT5-MMP. It is interesting to point out that the active
proteinase for MT5-MMP may also include the 28 kDa spe-
cies under some circumstances such as the shed one present in
culture supernatants of MT591 expressing the intact molecule.
Although BB94 can shift the dynamics from the 28 kDa to the
58 kDa ones when included in the culture medium (Fig. 1), it
is not clear whether the 58 kDa can be autocatalytically con-
verted into the 28 kDa species. If so, some of the substrate
degrading activities detected in our studies may represent the
activity of both the 58 kDa and 28 kDa species, similar to that
of stromelysin-3 [22,26]. Further investigation will be needed
to clarify the relative contribution of the 28 and 58 kDa spe-
cies as well as the membrane-bound vs. soluble forms of MT5-
MMP in pathobiological processes.
MT5-MMP has a short half-life as an active proteinase.
Based on data presented in this paper, it is clear that MT5-
MMP has a short half-life at physiological temperature. Al-
most 50% of the full-length ecto-enzyme undergoes autocata-
lytic destruction into smaller fragments. Although the half-life
for intact MT5-MMP on cell membrane has not been deter-
mined, this property along with its tendency to be shed from
cell surface serves to distinguish MT5-MMP from the other
MT-MMPs. It is interesting to note that its closest relative,
MT3-MMP, is degraded rapidly after maturation, although
detail stability studies have yet to be reported [19]. On the
other hand, MT1-MMP, with less sequence homology to
MT5-MMP, appears to be fairly stable [14]. Thus, the stability
of each MT-MMP may be a function of its primary amino
acid sequence and there may be speci¢c sequence determi-
nants for stability. Furthermore, the half-life of active en-
zymes, along with latency and TIMPs, may be a critical mech-
anism for MT-MMPs to achieve precise proteolytic activity at
ECM remodeling sites [11,13,14].
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